a3b44031-71ef-476f-a8bd-3694226ce026
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 82
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.630
- ALLOGRAFT_REJECTION+0.450
- INTERFERON_GAMMA_RESPONSE+0.430
- INTERFERON_ALPHA_RESPONSE+0.400
- IL6_JAK_STAT3_SIGNALING+0.390
- MYC_TARGETS_V1+0.380
- PROTEIN_SECRETION+0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- TNFA_SIGNALING_VIA_NFKB+0.350
- FATTY_ACID_METABOLISM+0.330
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.490
- HEDGEHOG_SIGNALING-0.460
- ANGIOGENESIS-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- MITOTIC_SPINDLE-0.270
- MYOGENESIS-0.260
- APICAL_SURFACE-0.250
- APICAL_JUNCTION-0.240
- KRAS_SIGNALING_DN-0.230
- TGF_BETA_SIGNALING-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2ad90ba0-8038-4bad-afa3-d176f63b42f0 | — | — | 0.895 |
| 2 | AUR-AERW-TTM1-A-1-1-R-A742-41 | — | C | 0.880 |
| 3 | 5ffcc7c5-661f-4eed-b5e6-ed158c668321 | — | — | 0.877 |
| 4 | TCGA-05-5425-01A-02R-1628-07 | — | cohortA4 | 0.851 |
| 5 | SRR9879275 | — | cohortA1 | 0.843 |
| 6 | TCGA-05-5420-01A-01R-1628-07 | — | cohortA1 | 0.843 |
| 7 | SRR12696807 | — | — | 0.840 |
| 8 | SRR23036888 | — | — | 0.838 |
| 9 | e0464181-da72-4a14-9039-a396843c39f2 | — | — | 0.837 |
| 10 | bc895549-854b-484f-8a6d-9e5152829bcb | — | — | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.630 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.380 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.180 | Inavolisib | — uncovered |